Results 171 to 180 of about 562,340 (252)

Treatment of Opioid-Induced Constipation: Inducing Laxation and Understanding the Risk of Gastrointestinal Perforation. [PDF]

J Clin Gastroenterol
Mehta N, Laitman AP, Brookfield RB, Harris LA.   +3 more
europepmc   +1 more source

MCV/Q, Medical College of Virginia Quarterly, Vol. 10 No. 2 [PDF]

, 1974

core   +1 more source

Intranasal Naloxone During Recurrent Exercise in Individuals with Type-1 Diabetes Mellitus: Evaluation of the Clinical Predictors of Pharmacokinetics and Exposure-Response. [PDF]

J Clin Pharmacol
Al Yacoub ON, Cheng S, Fayed MS, Fisher J, Brooks J, Seaquist E, Kumar A, Moheet A, Eberly L, Coles LD.   +9 more
europepmc   +1 more source

Use of Naltrexone for Patients With Stimulant Use Disorder in Malaysia: Protocol for a Retrospective Cohort Study.

JMIR Res Protoc
Muhamad NA, Ma'amor NH, Muhamad Rasat MA, Tengku Baharudin Shah TPN, Rosli '', Leman FN, Jamalluddin NH, Misnan NS, Chemi N, Abdullah N, Ibrahim N, My Addiction Study group.   +11 more
europepmc   +1 more source

Reversal of morphine-induced respiratory depression with the µ₁-opioid receptor antagonist naloxonazine engenders excitation and instability of breathing. [PDF]

Am J Physiol Lung Cell Mol Physiol
Getsy PM, May W, Henderson F, Coffee GA, Baby SM, Hsieh YH, Lewis SJ.   +6 more
europepmc   +1 more source

Ethical and Legal Aspects of Substance Use Disorder Treatment.

Focus (Am Psychiatr Publ)
Bernstein A.
europepmc   +1 more source

Carfentanil stabilizes µ opioid receptor conformations that are ultra-efficient in inhibiting cAMP, resistant to naloxone or nalmefene but sensitive to naltrexone. [PDF]

Arch Toxicol
Endt F, Guo T, Steinritz D, Amend N, Gudermann T, Breit A.   +5 more
europepmc   +1 more source

Naldemedine for the management of opioid-induced constipation in patients with cancer pain: A narrative review. [PDF]

Medicine (Baltimore)
Nishiba H, Imai H, Nagamine A, Takahashi Y, Obayashi K.   +4 more
europepmc   +1 more source

Investigating the effect of ondansetron in reducing myoclonic movements caused by intravenous administration of etomidate. [PDF]

BMC Anesthesiol
Alipour M, Firuzabadi SJP.
europepmc   +1 more source